Hemostemix is a clinical stage biotechnology company focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases. ACP , our lead clinical stage candidate, is an autologous cell therapy for the treatment critical limb ischemia. ACP is currently in a Phase clinical trail in Canada, South Africa and the United States.
Quote | Hemostemix Inc (OTCMKTS:HMTXF)
Last: | $0.046 |
---|---|
Change Percent: | 58.62% |
Open: | $0.024 |
Close: | $0.029 |
High: | $0.046 |
Low: | $0.024 |
Volume: | 16,515 |
Last Trade Date Time: | 07/22/2024 03:00:00 am |
News | Hemostemix Inc (OTCMKTS:HMTXF)
Calgary, Alberta--(Newsfile Corp. - June 11, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it was notified by the World Intellectual Property Organization that it was granted the trademark Your Fountain of Youth by the Swiss Trademark Office. "In four h...
2024-06-03 13:23:23 ET In a press release this morning, %Hemostemix Inc. (TSXV: $HEM) (OTC: $HMTXF) announced it had signed a Letter of Intent ("LOI") with CytoImmune Therapeutics. The LOI will re-establish production of ACP-01 ("ACP") in CytoImmune's state-of-the-art clinical cell manu...
Message Board Posts | Hemostemix Inc (OTCMKTS:HMTXF)
Subject | By | Source | When |
---|---|---|---|
The ongoing underperformance of $HMTXF's stock has raised red flags about its viability as a long-te | 10/31/2023 8:06:24 AM | ||
$HEM's stock price took a hit, falling by 15% to $0.085 in the previous trading session, translating | 10/30/2023 2:24:09 PM | ||
The persistent disappointment in $HEM's stock performance has cast doubt on its potential as a long- | 10/30/2023 9:55:13 AM | ||
lolapaluuza: Sounds very global. For a long time I couldn't solve the problem of tracking the workin | lolapaluuza | investorshangout | 05/05/2023 11:59:39 AM |
MatthewDavies: Hemostemix Inc. (TSXV: $HEM) (OTCQB: | MatthewDavies | investorshangout | 10/25/2022 5:29:19 PM |
News, Short Squeeze, Breakout and More Instantly...
Calgary, Alberta--(Newsfile Corp. - June 11, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it was notified by the World Intellectual Property Organization that it was granted the trademark Your Fountain of Youth by the Swiss Trademark Office. "In four h...
2024-06-03 13:23:23 ET In a press release this morning, %Hemostemix Inc. (TSXV: $HEM) (OTC: $HMTXF) announced it had signed a Letter of Intent ("LOI") with CytoImmune Therapeutics. The LOI will re-establish production of ACP-01 ("ACP") in CytoImmune's state-of-the-art clinical cell manu...
Calgary, Alberta--(Newsfile Corp. - June 3, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) is pleased to announce it has signed a Letter of Intent ("LOI") with CytoImmune Therapuetics ("CytoImmune") to re-establish production of ACP-01 ("ACP") in CytoImmune's state-of-the-art c...